Navigation Links
EPA to Improve Nanotechnology

The U.S. Environmental Protection Agency released its current thinking on whether a nanoscale material is a new or existing chemical substance under the Toxic Substances Control Act (TSCA).

In the document, TSCA Inventory Status of Nanoscale SubstancesGeneral Approach, EPA states that it will maintain its practice of determining whether nanoscale substances qualify as new chemicals under TSCA on a case-by-case basis.

According to former EPA official and Project on Emerging Nanotechnologies (PEN) senior advisor J. Clarence Davies, The agencys current practice is inadequate to deal with nanotechnology. It is essential that EPA move quickly to recognize the novel biological and ecological characteristics of nanoscale materials.

It can do this only by using the new uses provisions of TSCA, a subject not mentioned in the EPAs inventory document. With the approach outlined by EPA and because of the weaknesses in the law, the agency is not even able to identify which substances are nanomaterials, much less determine whether they pose a hazard.

Project on Emerging Nanotechnologies science advisor Andrew Maynard underlined that EPAs approach ignores the scientific research evidence to date that different nanostructures with the same molecular identity present different hazards.

Nanotechnology is a rapidly growing sector of the economy that will represent an estimated 2.6 trillion dollars in manufactured goods by 2014, or about 15 percent of global manufactured goods output.

In addition to the TSCA document, the agency issued papers for public comment pertaining to a proposed voluntary industry Nanoscale Materials Stewardship Program (NMSP)an effort to encourage industry to provide the agency on a voluntary basis with scientific information about the risk management practices now used by manufacturers of existing nanomaterials.

Starting the Stewardship program will be a positive s
'"/>




Page: 1 2 3

Related medicine news :

1. Hypertensive Drug Improves Sexual Dysfunction in Hypertensive Men
2. Steps To Improve Quality Of Plant-Based Drugs
3. Almonds Improve Cholesterol
4. How to Improve Life Expectancy
5. Sage Improves Memory
6. Protein said to Improve Muscle Loss
7. Ultrasound Screening Could Improve The Outcome Of Critically ill Patients
8. New Drug Combination Found To Improve Memory in Alzheimer’s Patient
9. Vitamin B12 Supplements Found To Improve Memory
10. A Loving Relationship Found To Improve Heart Health
11. Fish Found To Improve Fetal Growth
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: EPA Improve Nanotechnology

Breaking Medicine Technology:Reportlinker Adds Trauma Devices - Trends & Opportunities Worldwide 2Reportlinker Adds Trauma Devices - Trends & Opportunities Worldwide 3Reportlinker Adds Trauma Devices - Trends & Opportunities Worldwide 4Reportlinker Adds Trauma Devices - Trends & Opportunities Worldwide 5Reportlinker Adds Trauma Devices - Trends & Opportunities Worldwide 6Reportlinker Adds Trauma Devices - Trends & Opportunities Worldwide 7Reportlinker Adds Trauma Devices - Trends & Opportunities Worldwide 8Reportlinker Adds Trauma Devices - Trends & Opportunities Worldwide 9Reportlinker Adds Cardiac Biomarkers - A Global Market Perspective 2Reportlinker Adds Cardiac Biomarkers - A Global Market Perspective 3Reportlinker Adds Cardiac Biomarkers - A Global Market Perspective 4Reportlinker Adds Cardiac Biomarkers - A Global Market Perspective 5Reportlinker Adds Cardiac Biomarkers - A Global Market Perspective 6Reportlinker Adds Cardiac Biomarkers - A Global Market Perspective 7Reportlinker Adds Cardiac Biomarkers - A Global Market Perspective 8Reportlinker Adds Radiation Therapy Equipment - A Global Market Review 2Reportlinker Adds Radiation Therapy Equipment - A Global Market Review 3Reportlinker Adds Radiation Therapy Equipment - A Global Market Review 4Reportlinker Adds Radiation Therapy Equipment - A Global Market Review 5Reportlinker Adds Radiation Therapy Equipment - A Global Market Review 6Reportlinker Adds Radiation Therapy Equipment - A Global Market Review 7Reportlinker Adds Radiation Therapy Equipment - A Global Market Review 8Patient Enrollment Complete for Phase I II Clinical Trial for GALNS for Morquio A Syndrome 51451 1Patient Enrollment Complete for Phase I II Clinical Trial for GALNS for Morquio A Syndrome 51451 2Patient Enrollment Complete for Phase I II Clinical Trial for GALNS for Morquio A Syndrome 51451 3Patient Enrollment Complete for Phase I II Clinical Trial for GALNS for Morquio A Syndrome 51451 4Good Nutrition Can Fuel the Whole Family Even the Four Legged Members 51449 1Good Nutrition Can Fuel the Whole Family Even the Four Legged Members 51449 2Good Nutrition Can Fuel the Whole Family Even the Four Legged Members 51449 3Monitoring Circulating Tumor Cells With the CellSearch 28R 29 System Can Predict Prognosis in Metastatic Breast Cancer 12986 1Monitoring Circulating Tumor Cells With the CellSearch 28R 29 System Can Predict Prognosis in Metastatic Breast Cancer 12986 2Monitoring Circulating Tumor Cells With the CellSearch 28R 29 System Can Predict Prognosis in Metastatic Breast Cancer 12986 3Monitoring Circulating Tumor Cells With the CellSearch 28R 29 System Can Predict Prognosis in Metastatic Breast Cancer 12986 4
Other Medicine Technology:New Data on SEROQUEL XR(TM) in Treatment of Both Major Depressive Disorder and Generalized Anxiety Disorder Presented at APA Annual Meeting 2New Data on SEROQUEL XR(TM) in Treatment of Both Major Depressive Disorder and Generalized Anxiety Disorder Presented at APA Annual Meeting 3New Data on SEROQUEL XR(TM) in Treatment of Both Major Depressive Disorder and Generalized Anxiety Disorder Presented at APA Annual Meeting 4New Data on SEROQUEL XR(TM) in Treatment of Both Major Depressive Disorder and Generalized Anxiety Disorder Presented at APA Annual Meeting 5New Data on SEROQUEL XR(TM) in Treatment of Both Major Depressive Disorder and Generalized Anxiety Disorder Presented at APA Annual Meeting 6New Data on SEROQUEL XR(TM) in Treatment of Both Major Depressive Disorder and Generalized Anxiety Disorder Presented at APA Annual Meeting 7New Data on SEROQUEL XR(TM) in Treatment of Both Major Depressive Disorder and Generalized Anxiety Disorder Presented at APA Annual Meeting 8New Data on SEROQUEL XR(TM) in Treatment of Both Major Depressive Disorder and Generalized Anxiety Disorder Presented at APA Annual Meeting 9New Data on SEROQUEL XR(TM) in Treatment of Both Major Depressive Disorder and Generalized Anxiety Disorder Presented at APA Annual Meeting 10New Data on SEROQUEL XR(TM) in Treatment of Both Major Depressive Disorder and Generalized Anxiety Disorder Presented at APA Annual Meeting 11New Data on SEROQUEL XR(TM) in Treatment of Both Major Depressive Disorder and Generalized Anxiety Disorder Presented at APA Annual Meeting 12New Data on SEROQUEL XR(TM) in Treatment of Both Major Depressive Disorder and Generalized Anxiety Disorder Presented at APA Annual Meeting 13New Data on SEROQUEL XR(TM) in Treatment of Both Major Depressive Disorder and Generalized Anxiety Disorder Presented at APA Annual Meeting 14Clinical Data Demonstrates 5-Year Efficacy and Safety of Aquamid(R) in Facial Augmentation 2Clinical Data Demonstrates 5-Year Efficacy and Safety of Aquamid(R) in Facial Augmentation 3